Prime MedicinevsThermo Fisher Scientific

PRME and TMO stock compared: price, dividend, valuation and results, from SEC filings.

PRME

Prime Medicine, Inc.

$3.55

Value $641M

-7.55%
PRME's page

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

Prime Medicine (PRME) has a market value of $641M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, PRME moved -4.6% and TMO +17.1%. Dividend yield: PRME none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    PRME$641M

    TMO$249B

    TMO is 388 times PRME

  • Revenue, 12 months

    PRME$7.1M

    TMO$47.4B

    TMO is 6,706 times PRME

  • Net income, 12 months

    PRME-$176M

    TMO$7.1B

  • Operating margin

    PRME-2,584.2%

    TMO17.9%

    2,602.1 points apart

  • ROIC

    PRME-176.8%

    TMO8.2%

    185.0 points apart

  • P/E

    PRME–

    TMO35.2

  • Dividend yield

    PRME0.0%

    TMO0.3%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

PRME-48.9%

TMO+44.1%

50100150202420252026
Returns by period
PeriodPRMEWith dividendsTMOWith dividends
1 year since November 19, 2025-4.6%Price -4.6%+17.1%Price +16.7%
3 years since November 20, 2023-48.9%-20.1% a yearPrice -48.9%+44.1%+13.0% a yearPrice +42.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

PRMEPrime MedicineTMOThermo Fisher Scientific

Valuation

PRMETMO
Valuation
Price$3.55$669.54
Market value$641M$249B
Enterprise value (EV)$580M$284B
P/E–35.2
P/E, 5-year median–32.7
P/B76.04.5
EV/EBIT–33.5
Free cash flow yield–3.1%

Results and growth

PRMETMO
Results and growth
Revenue, 12 months$7.1M$47.4B
Net income, 12 months-$176M$7.1B
Free cash flow, 12 months-$159M$7.6B
Earnings per share, 12 months-$0.98$18.96
Revenue growth, year on year55.3%3.9%
Revenue growth a year, past-2.3%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

PRMETMO
Margins and returns on capital
Gross margin––
Operating margin-2,584.2%17.9%
Net margin-2,497.6%14.9%
ROIC-176.8%8.2%
ROE-216.3%13.4%

Balance sheet

PRMETMO
Balance sheet
Cash$61M$6.1B
Total debt$110M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

PRMETMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: PRME or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Prime Medicine or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($249B) is about 388.0 times Prime Medicine ($641M), at today's prices.

How did PRME and TMO stock do over the last 3 years?

Since November 20, 2023, PRME's price moved -48.9% and TMO's +42.7%. With dividends: PRME -48.9% (-20.1% a year), TMO +44.1% (+13.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, PRME or TMO?

The dividend yield at today's price is none for Prime Medicine and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Prime Medicine or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -2,497.6% for Prime Medicine and 14.9% for Thermo Fisher Scientific, and the operating margin -2,584.2% and 17.9%. Revenue was $7.1M and $47.4B.

Which is the better investment, Prime Medicine or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.